Analysts Set Privia Health Group, Inc. (NASDAQ:PRVA) PT at $24.92

Shares of Privia Health Group, Inc. (NASDAQ:PRVA) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $24.92.

A number of equities analysts recently commented on the company. Barclays reduced their price objective on Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Monday, May 20th. TD Cowen dropped their price objective on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Baird R W raised shares of Privia Health Group to a “strong-buy” rating in a research note on Thursday, May 30th. UBS Group dropped their price target on shares of Privia Health Group from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, March 1st. Finally, Truist Financial cut their price target on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, May 15th.

Insider Buying and Selling

In other news, CFO David Mountcastle sold 2,320 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total value of $42,734.40. Following the completion of the transaction, the chief financial officer now owns 259,959 shares of the company’s stock, valued at $4,788,444.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Privia Health Group news, CFO David Mountcastle sold 2,320 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $42,734.40. Following the sale, the chief financial officer now directly owns 259,959 shares in the company, valued at approximately $4,788,444.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Parth Mehrotra sold 12,219 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $225,073.98. Following the completion of the transaction, the chief executive officer now directly owns 261,640 shares of the company’s stock, valued at approximately $4,819,408.80. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 293,235 shares of company stock valued at $4,745,481 and have sold 49,390 shares valued at $897,700. 14.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PRVA. Park Place Capital Corp lifted its position in shares of Privia Health Group by 115.4% during the 1st quarter. Park Place Capital Corp now owns 2,492 shares of the company’s stock worth $49,000 after purchasing an additional 1,335 shares during the last quarter. Benjamin Edwards Inc. lifted its holdings in Privia Health Group by 44.9% during the 4th quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company’s stock worth $75,000 after buying an additional 1,003 shares during the last quarter. Covestor Ltd lifted its holdings in Privia Health Group by 25.5% during the 1st quarter. Covestor Ltd now owns 5,292 shares of the company’s stock worth $104,000 after buying an additional 1,076 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Privia Health Group during the 1st quarter worth about $131,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in shares of Privia Health Group in the 4th quarter valued at about $158,000. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Stock Performance

NASDAQ PRVA opened at $16.48 on Friday. The business has a fifty day moving average price of $17.52 and a 200 day moving average price of $19.84. The company has a market cap of $1.97 billion, a P/E ratio of 109.87, a P/E/G ratio of 2.61 and a beta of 0.78. Privia Health Group has a one year low of $15.92 and a one year high of $28.23.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, May 9th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.03). The business had revenue of $415.24 million during the quarter, compared to analyst estimates of $435.07 million. Privia Health Group had a net margin of 1.11% and a return on equity of 3.13%. As a group, sell-side analysts predict that Privia Health Group will post 0.2 EPS for the current fiscal year.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.